Niagen Bioscience Inc Dossier - Source-backed chat

Niagen Bioscience Inc

NAGENASDAQ

SectorConsumer Staples

IndustryPersonal Care Products

Beta (adjusted)1.74

Intrinsic Value $2.95median of 6 methods · middle span $2-$3based on filings through 30 Jun 2026

Market Price $2.68Price as of 1 Oct 2026

Near fair valueIntrinsic value is 10% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $213.4M

Enterprise Value $149.3M

Shares Outstanding 84M diluted

Moat Rating Wide

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Niagen Bioscience, Inc. (formerly ChromaDex Corp.) is the global authority on NAD+ (nicotinamide adenine dinucleotide) science and healthy aging. Centered on its patented nicotinamide riboside (NR) chloride ingredient, Niagen®, the company has successfully transitioned into a highly profitable, high-margin bioscience platform. By divesting its non-core Analytical Reference Standards segment in February 2026, Niagen has streamlined its operations to focus entirely on its core consumer brand (Tru Niagen®) and its rapidly growing clinical channel (Niagen Plus™). With a robust patent estate, expanding clinical validation, and new direct-to-patient telehealth initiatives, the company is well-positioned to capitalize on the secular longevity boom.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.00

Mean target$12.50

High · most bullish analyst$22.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$4.5010%

Top-line growth is constrained by persistent order variability from major B2B partners like A.S. Watson, while increased sales, marketing, and R&D investments compress operating margins. Regulatory hurdles or competitive pressures from alternative NAD+ precursors like NMN slow consumer adoption.

Base CaseCentral scenario

$12.5060%

Matches the consensus mean

The company achieves its guided 10-15% net sales growth for FY 2026 (excluding the divested segment), anchored by steady 14% e-commerce growth and stable food-grade ingredient sales. Gross margins remain strong at approximately 63.5-64%, and disciplined G&A spending supports consistent profitability.

Bull CaseUpside scenario

$16.3330%

Rapid adoption of the newly launched Niagen Plus telehealth platform and at-home injection kits, combined with international expansion and high-margin e-commerce growth, drives revenue growth well above the guided 10-15% range. Operating leverage scales significantly, pushing gross margins past 65% and accelerating net income growth.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Unmatched scientific foundation with over 45 peer-reviewed published clinical studies and a robust patent portfolio protecting NR and other NAD+ precursors.
Streamlined business model following the divestiture of the Analytical Reference Standards segment, allowing 100% focus on high-margin NAD+ commercialization.
Strong balance sheet with $66.5 million in cash, no outstanding debt, and an active share repurchase program expanded to $20 million.
High-barrier clinical entry via Niagen Plus, supported by partnerships with 503B compounding facilities and premium wellness channels like OneSpaWorld.

Key Investment Risks

High concentration on a single-molecule platform (nicotinamide riboside), making the company vulnerable to any negative scientific or regulatory developments regarding NR.
Revenue dependency on key B2B relationships, such as A.S. Watson, which introduces quarterly order volatility.
Rising operating expenses as the company accelerates brand, infrastructure, and clinical telehealth investments.

Thesis Invalidation Triggers

A major regulatory shift by the FDA or global authorities restricting the sale or compounding of nicotinamide riboside.
A significant decline in e-commerce growth, indicating saturation of the core Tru Niagen consumer market.
Failure of the Niagen Plus telehealth and injection platform to gain commercial traction among clinicians and patients.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.